Corcept Therapeutics Incorporated announced that On August 10, 2021, Andreas Grauer, M.D. separated from his position as Chief Medical Officer of Corcept Therapeutics Incorporated (the “Company”). Dr. Grauer has agreed to serve as a senior medical advisor to the Company to assist with its development programs and to help transition his responsibilities to the Company’s Chief Development Officer. On August 11, 2021, Dr. Grauer and the Company entered into a Separation Agreement, pursuant to which Dr. Grauer is entitled to receive, in addition to any final wages owed to him, the following benefits: continuation of his salary for a one-year period commencing on the separation date (the “Severance Period”); payment of, or reimbursement for, the Company’s portion of the COBRA premium for Dr. Grauer and his covered dependents through the earlier of the end of the Severance Period or the date he and his covered dependents become eligible for healthcare coverage under another employer’s plan; and continuation of Dr. Grauer’s quarterly housing allowance through the earlier of the end of the Severance Period or the termination of the current term of Dr. Grauer’s lease (collectively, the “Separation Benefits”). The Separation Benefits are conditioned upon Dr. Grauer executing and not revoking a general release of claims in favor of the Company and his continued compliance with certain restrictive covenants.